Langlui's Big Board and Options Plays

[TechKim]

Major RLYP double news release today.

http://investor.relypsa.com/releasedetail.cfm?ReleaseID=926942

http://investor.relypsa.com/releasedetail.cfm?ReleaseID=926931

$40 million upfront from Vifor Fresenius. Up to $125 million
Under the terms of the agreement, Relypsa will receive an upfront cash payment of $40 million and will be eligible to receive payments of up to $125 million upon achieving certain regulatory and sales based milestones. In addition, Relypsa will receive tiered double-digit royalties on net sales of Patiromer FOS in the licensed territories. VFMCRP will obtain an exclusive marketing right from Relypsa in worldwide territories except the United States and Japan, where Relypsa retains all commercial rights. Relypsa and VFMCRP will collaborate on ongoing development of Patiromer FOS, including submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA).

Sanofi sales force has been partnered in the United States also.

RLYP holds all rights in Japan also.

conference call replay on their website in regards to partnerships
http://investor.relypsa.com/events.cfm